Resultados da pesquisa - Laurence Albigès

Refinar resultados
  1. 1
    Nivolumab in renal cell carcinoma: latest evidence and clinical potential

    Nivolumab in renal cell carcinoma: latest evidence and clinical potential Por Camille Mazza, Bernard Escudier, Laurence Albigès

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  2. 2
    Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma

    Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma Por Elie Rassy, Ronan Flippot, Laurence Albigès

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  3. 3
    ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer

    ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer Por Karim Fizazi, Laurence Albigès, Yohann Loriot, Christophe Massard

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  4. 4
    Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma

    Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma Por Hassan Izzedine, Lisa Derosa, Gwénaël Le Teuff, Laurence Albigès, Bernard Escudier

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  5. 5
    Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases

    Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases Por Laurence Albigès, Fabrice André, Corinne Balleyguier, Gonzalo Gomez-Abuin, Agnès Chompret, Suzette Delaloge

    Publicado em 2005
    Obter o texto integral Obter o texto integral
    Carta
    Adic. favoritos
    Na minha lista:
  6. 6
    TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma

    TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma Por Laurence Albigès, Philippe Barthélémy, Marine Gross‐Goupil, Sylvie Négrier, Michael N. Needle, Bernard Escudier

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  7. 7
    Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma

    Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma Por Laurence Albigès, Foucauld Chamming’s, Brigitte Duclos, M. Stern, Robert J. Motzer, Alain Ravaud, P. Camus

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  8. 8
    Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography

    Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography Por Nathalie Lassau, Serge Koscielny, Laurence Albigès, L. Chami, Baya Benatsou, Mohamed Chébil, Alain Roche, Bernard Escudier

    Publicado em 2010
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  9. 9
    Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma

    Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma Por Christophe Maritaz, David Combarel, Cécile Dalban, Louis Blondel, Sophie Broutin, Aurélien Marabelle, Laurence Albigès, Angélo Paci

    Publicado em 2025
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  10. 10
    Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events

    Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events Por Viktor Grünwald, Martin H. Voss, Brian I. Rini, Thomas Powles, Laurence Albigès, Rachel H. Giles, Eric Jonasch

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  11. 11
    Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

    Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients Por Luc Cabel, Elika Loir, Gwénaëlle Gravis, Pernelle Lavaud, Christophe Massard, Laurence Albigès, Giulia Baciarello, Yohann Loriot, Karim Fizazi

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  12. 12
    Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma

    Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma Por Guillermo de Velasco, Katherine M. Krajewski, Laurence Albigès, Mark M. Awad, Joaquim Bellmunt, F. Stephen Hodi, Toni K. Choueiri

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  13. 13
    ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma

    ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma Por Thomas Powles, Laurence Albigès, Axel Bex, Viktor Grünwald, Camillo Porta, Giuseppe Procopio, Manuela Schmidinger, Cristina Suárez, Guillermo de Velasco

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  14. 14
    Who dies from prostate cancer?

    Who dies from prostate cancer? Por Anna Patrikidou, Yohann Loriot, J-C Eymard, Laurence Albigès, Christophe Massard, E. Ileana, Mario Di Palma, Bernard Escudier, Karim Fizazi

    Publicado em 2014
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  15. 15
    Renal cell carcinoma

    Renal cell carcinoma Por James J. Hsieh, Mark P. Purdue, Sabina Signoretti, Charles Swanton, Laurence Albigès, Manuela Schmidinger, Daniel Y.C. Heng, James Larkin, Vincenzo Ficarra

    Publicado em 2017
    Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  16. 16
    Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

    Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Por Yohann Loriot, Diletta Bianchini, E. Ileana, Shahneen Sandhu, Anna Patrikidou, Carmel Pezaro, Laurence Albigès, Gerhardt Attard, Karim Fizazi, Johann S. de Bono, Christophe Massard

    Publicado em 2013
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  17. 17
    Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience

    Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience Por Baptiste Bonnet, Louis Tournier, Frédèric Deschamps, Steven Yevich, Aurélien Marabelle, Caroline Robert, Laurence Albigès, Benjamin Besse, V Bonnet, Thierry de Baère, Lambros Tselikas

    Publicado em 2024
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  18. 18
    Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma

    Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma Por Anthony Saroufim, Yosra Messai, Meriem Hasmim, Nathalie Rioux, Roberto Iacovelli, G. Verhoest, Karim Bensalah, J-J Patard, Laurence Albigès, Bruno Azzarone, Bernard Escudier, Salem Chouaı̈b

    Publicado em 2014
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  19. 19
    Chk1 as a new therapeutic target in triple-negative breast cancer

    Chk1 as a new therapeutic target in triple-negative breast cancer Por Laurence Albigès, Aïcha Goubar, Véronique Scott, Cécile Vicier, Céline Lefèbvre, Samar Alsafadi, Frédéric Commo, Mahasti Saghatchian, Vladimir Lazar, Philippe Dessen, Suzette Delaloge, Fabrice André, Virginie Quidville

    Publicado em 2014
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  20. 20
    Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors

    Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors Por Sarah C. Markt, Carlos Lago‐Hernandez, Rowan Miller, Brandon A. Mahal, Brandon Bernard, Laurence Albigès, Lindsay A. Frazier, Clair J. Beard, Alexi A. Wright, Christopher J. Sweeney

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: